Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction

被引:153
作者
Wagner, HJ
Wessel, M
Jabs, W
Smets, F
Fischer, L
Offner, G
Bucsky, P
机构
[1] Med Univ Lubeck, Dept Pediat, D-23538 Lubeck, Germany
[2] Med Univ Lubeck, Dept Internal Med, D-23538 Lubeck, Germany
[3] Hannover Med Sch, Dept Pediat, D-3000 Hannover, Germany
[4] Catholic Univ Louvain, Dept Pediat, Brussels, Belgium
关键词
D O I
10.1097/00007890-200109270-00006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Early diagnosis of Epstein-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) is required to detect a stage of disease that is more likely to respond to treatment. Elevated levels of EBV DNA were found in peripheral blood of patients at the onset of PTLD. Methods. To compare plasma and peripheral blood mononuclear cells (PBMCs) as material for real-time quantitative polymerase chain reaction (RQ-PCR) measurement of Epstein-Barr viral load, we used two sets of primers and probes specific for the BAM HI-K or RAM HI-W region of the EBV genome. Results. Patients with PTLD had a median viral load of 19,200 EBV genomes/mug DNA (n=9) or 3,225 EBV genomes/100 mul plasma (n=5), being significantly higher compared with immunosuppressed patients with primary (n=9) or reactivated (n=20) EBV infection or immunosuppressed patients without serological signs of active EBV infection (n=67) (P <0.001). Hence, a value of greater than 5,000 EBV genomes/mug PBMC DNA was considered as a diagnostic parameter for PTLD with a sensitivity and specificity of 1.00 or 0.89, respectively. When plasma was analyzed, however, a value of greater than 1,000 EBV genomes/100 ttl plasma had both a sensitivity and specificity of 1.00 for the diagnosis of PTLD. During remission of PTLD, viral load was more effectively cleared in plasma compared with PBMCs. In plasma of nonimmunosuppressed individuals, even a qualitative detection of EBV-related sequences was sensitive and specific for the diagnosis of primary EBV infection, whereas for analysis of PBMC DNA a quantitative parameter had to be considered to differentiate healthy individuals (< 100 EBV genomes/mug PBMC DNA) from patients with primary EBV infection (> 100 EBV genomes/mug PBMC DNA). Conclusion. Although both PBMCs and plasma were useful as material for EBV-specific RQ-PCR in immunosuppressed patients and nonimmunosuppressed individuals, the specificity of analysis seemed to be higher if plasma was taken for analysis.
引用
收藏
页码:1012 / 1019
页数:8
相关论文
共 42 条
  • [31] Rickinson A., 1996, FIELDS VIROL, V2, P2397
  • [32] RIDDLER SA, 1994, BLOOD, V84, P972
  • [33] EARLY IDENTIFICATION OF EPSTEIN-BARR VIRUS-ASSOCIATED POSTTRANSPLANTATION LYMPHOPROLIFERATIVE DISEASE
    ROONEY, CM
    LOFTIN, SK
    HOLLADAY, MS
    BRENNER, MK
    KRANCE, RA
    HESLOP, HE
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 98 - 103
  • [34] Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
    Rooney, CM
    Smith, CA
    Ng, CYC
    Loftin, SK
    Sixbey, JW
    Gan, YJ
    Srivastava, DK
    Bowman, LC
    Krance, RA
    Brenner, MK
    Heslop, HE
    [J]. BLOOD, 1998, 92 (05) : 1549 - 1555
  • [35] Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders
    Rowe, DT
    Qu, L
    Reyes, J
    Jabbour, N
    Yunis, E
    Putnam, P
    Todo, S
    Green, M
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1997, 35 (06) : 1612 - 1615
  • [36] Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
    Sokal, EM
    Antunes, H
    Beguin, C
    Bodeus, M
    Wallemacq, P
    deGoyet, JD
    Reding, R
    Janssen, M
    Buts, JP
    Otte, JB
    [J]. TRANSPLANTATION, 1997, 64 (10) : 1438 - 1442
  • [37] Monitoring of Epstein-Barr virus DNA load in peripheral blood by quantitative competitive PCR
    Stevens, SJC
    Vervoort, MBHJ
    van den Brule, AJC
    Meenhorst, PL
    Meijer, CJLM
    Middeldorp, JM
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (09) : 2852 - 2857
  • [38] Swerdlow AJ, 2000, TRANSPLANTATION, V69, P897
  • [39] AN EPSTEIN-BARR VIRUS-PRODUCER LINE AKATA - ESTABLISHMENT OF THE CELL-LINE AND ANALYSIS OF VIRAL-DNA
    TAKADA, K
    HORINOUCHI, K
    ONO, Y
    AYA, T
    OSATO, T
    TAKAHASHI, M
    HAYASAKA, S
    [J]. VIRUS GENES, 1991, 5 (02) : 147 - 156
  • [40] DETECTION AND QUANTIFICATION OF LATENTLY INFECTED LYMPHOCYTES-B IN EPSTEIN-BARR VIRUS-SEROPOSITIVE, HEALTHY-INDIVIDUALS BY POLYMERASE CHAIN-REACTION
    WAGNER, HJ
    BEIN, G
    BITSCH, A
    KIRCHNER, H
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (11) : 2826 - 2829